CN112168912A

CN112168912A - Plant compound capable of inhibiting acne-related pathogenic bacteria and application thereof

Info

Publication number: CN112168912A
Application number: CN202011057271.2A
Authority: CN
Inventors: 王飞飞; 吴信浪; 曲丽萍; 马骁; 高绍阳; 郭振宇
Original assignee: Shanghai Beitaini Biotechnology Co ltd; Shanghai Jiyan Biomedical Development Co ltd; Yunnan Beitani Biotechnology Group Co ltd
Current assignee: Shanghai Beitaini Biotechnology Co ltd; Shanghai Jiyan Biomedical Development Co ltd; Yunnan Beitani Biotechnology Group Co ltd
Priority date: 2020-09-30
Filing date: 2020-09-30
Publication date: 2021-01-05

Abstract

The invention discloses a plant compound capable of inhibiting acne-related pathogenic bacteria, which comprises the following components in parts by weight: 10-40 parts of paris polyphylla stem and leaf extract; 10-40 parts of magnolia officinalis extract; 10-40 parts of rhubarb extract, and the sum of the parts by weight of the plant extracts is 100 parts, so that the composition has the excellent characteristics of high safety, obvious acne inhibition and the like, and has good market value and application prospect. The invention also discloses an application of the plant compound for inhibiting the pathogenic bacteria related to the acne.

Description

Plant compound capable of inhibiting acne-related pathogenic bacteria and application thereof

Technical Field

The invention relates to the technical field of cosmetics, and particularly relates to a plant compound capable of inhibiting acne-related pathogenic bacteria and application thereof.

Background

Acne is one of the most common skin problems, commonly called as whelk, and is mainly characterized in that the skin secretes more oil components due to the increase of the androgenic hormones in the puberty period, and if the acne is infected by microorganisms such as propionibacterium acnes and the like, inflammation is easily caused, so that different types of rashes such as comedo, pimple, pustule and the like are formed. The moderate and severe acne not only can obviously affect the color value of the teenagers, but also can generate great negative effects on the psychology, social contact and the like of the teenagers.

At present, the acne removing products sold in the market often use chemically synthesized or even antibiotic acne removing components to achieve the acne removing effect, and the acne removing products often have drug resistance and potential safety hazards. For example:

the guidance report of medicine, 2019,38(12):1604-1605, published in "erectile dysfunction and hyposexuality caused by isotretinoin soft capsule" of Liu Long, etc., and studied that the common acne removing component isotretinoin may cause male sexual dysfunction and hyposexuality.

The Chinese journal of dermatology, 2014, (02): 131-.

Many natural plants have good acne removing and acne inhibiting effects, and an optional way is provided for solving the problems of drug resistance and potential safety hazards. For example:

the evaluation of the antibacterial effect of the total saponins of paris polyphylla and different saponin components on pathogenic bacteria related to acne is published in the journal of dermatology and pathology of China, 2016, and researches show that the saponins I, II, VI and VII of paris polyphylla in the total saponins of paris polyphylla have clear inhibition effect on bacteria related to acne in vitro, wherein the saponins I of paris polyphylla have the strongest antibacterial effect.

The research on the in-vitro bacteriostatic action of rhubarb on the main pathogenic bacteria of acne is found that free anthraquinone of rhubarb, such as emodin and chrysophanol, has a strong inhibitory effect on the main pathogenic bacteria of acne.

The study of the activity screening of 15 crude drug extracts for inhibiting acne pathogenic bacteria in chapter Mingmei and the like is published in the university of Jiangsu (medical edition), 2004,14(003): 188-.

The invention aims to find a pure plant compound which has an efficient acne removing effect and can reduce drug resistance and potential safety hazards. Compared with the reports of other researchers, no report is found on compounding the paris polyphylla, the rheum officinale and the mangnolia officinalis into the acne-removing plant compound.

Disclosure of Invention

The invention aims to overcome the defects of the prior art, and provides a plant compound capable of inhibiting pathogenic bacteria related to acne, which has the excellent characteristics of high safety, obvious inhibition on acne and the like, has no chemically synthesized acne-removing components, has no drug resistance and potential safety hazards, and has good market value and application prospect.

It is another object of the present invention to provide a use of phytocomplexes for inhibiting acne related pathogens.

One technical scheme for achieving the purpose is as follows: a plant compound for inhibiting acne related pathogenic bacteria comprises the following components in parts by weight:

10-40 parts of paris polyphylla stem and leaf extract;

10-40 parts of magnolia officinalis extract;

10-40 parts of a rhubarb extract;

the sum of the parts by weight of the paris polyphylla stem and leaf extract, the magnolia officinalis extract and the rhubarb extract is 100 parts.

The plant compound capable of inhibiting acne-related pathogenic bacteria is prepared by the following steps of: weighing a proper amount of dried paris polyphylla stem and leaf medicinal materials, crushing, adding the crushed medicinal materials into an alcohol/water mixed solution, performing reflux extraction for 1-4 times, mixing obtained extracting solutions, and sequentially performing reduced pressure concentration and water bath evaporation to dryness to obtain a crude extract of paris polyphylla stem and leaf; separating and purifying the crude extract of the stems and leaves of the paris polyphylla by macroporous resin to obtain the extract of the stems and leaves of the paris polyphylla;

during each extraction, the material-liquid ratio of the dry paris polyphylla stem and leaf medicinal materials to the alcohol/water mixed solution is 1: 6-1: 20 kg/L;

the alcohol in the alcohol/water mixed solution is one or more of methanol, ethanol, pentanediol and butanediol;

the volume fraction of the alcohol in the alcohol/water mixed solution is 30-95 percent;

the macroporous resin is one or more of D101, AB-8, HPD-100 and DM-301 macroporous resin.

The plant compound for inhibiting the acne-related pathogenic bacteria is characterized in that the content of the paris polyphylla saponin II in the paris polyphylla stem and leaf extract is not less than 3%, and the content of the dioscin is not less than 3.5%.

The plant compound for inhibiting acne-related pathogenic bacteria is prepared by the following steps of: weighing a proper amount of magnolia officinalis dry medicinal materials, crushing, adding the crushed magnolia officinalis dry medicinal materials into an alcohol/water mixed solution, performing reflux extraction for 1-4 times, mixing obtained extracting solutions, and performing reduced pressure concentration and water bath evaporation to dryness in sequence to obtain a magnolia officinalis extract;

in each extraction, the material-liquid ratio of the dry magnolia officinalis medicinal materials to the alcohol/water mixed solution is 1: 6-1: 20 kg/L;

the volume fraction of the alcohol in the alcohol/water mixed solution is 30-95%.

The plant compound capable of inhibiting pathogenic bacteria related to acne is characterized in that the mass percentage of honokiol in the magnolia bark extract is not less than 3.5%, and the mass percentage of magnolol is not less than 6.5%.

The plant compound for inhibiting the acne-related pathogenic bacteria is prepared by the following steps of: weighing a proper amount of dried rhubarb, crushing, adding the crushed dried rhubarb into an alcohol/water mixed solution, performing reflux extraction for 1-4 times, mixing obtained extracting solutions, and performing reduced pressure concentration and water bath evaporation to dryness in sequence to obtain a rhubarb extract;

during each extraction, the material-liquid ratio of the dried rhubarb and the alcohol/water mixed solution is 1: 6-1: 20 kg/L;

The plant compound capable of inhibiting acne-related pathogenic bacteria is characterized in that the mass percentage of chrysophanol in the rheum officinale extract is not less than 1%.

The invention also provides an application of the phytocomplex for inhibiting the acne-related pathogenic bacteria, wherein the phytocomplex is added into cosmetics, and the mass of the phytocomplex is 0.3-0.5% of the total mass of the cosmetics; the cosmetic is moisturizing cream or moisturizing lotion.

The application of the plant compound for inhibiting the acne-related pathogenic bacteria is characterized in that the moisturizing cream comprises the following components in parts by weight: 0.01-0.05 part of acrylic acid (ester), 0.8-1.2 parts of polydimethylsiloxane, 0.01-0.03 part of xanthan gum, 0.01-0.03 part of sodium hyaluronate, 0.01-0.03 part of hyaluronic acid, 1-3 parts of tridecanol trimellitate, 1-3 parts of shea butter, 0.05-0.15 part of prinsepia utilis royle oil, 0.5-0.15 part of glycerol stearate, 1-5 parts of purslane extract, 0.05-0.15 part of aminomethyl propanol, 0.3-0.5 part of plant compound and the balance of water;

the sum of the weight parts of the components of the moisturizing cream is 100 parts.

The application of the plant compound for inhibiting the acne-related pathogenic bacteria is characterized in that the emollient water comprises the following components in parts by weight: 1-5 parts of glycerol, 261-5 parts of glycerol polyether, 0.03-0.08 part of hydroxyethyl cellulose, 0.01-0.05 part of sodium hyaluronate, 1-5 parts of beta-glucan, 1-5 parts of purslane extract, 0.3-0.5 part of the plant compound and the balance of water;

the sum of the parts by weight of the components of the emollient water is 100 parts.

The technical scheme of the plant compound for inhibiting the pathogenic bacteria related to the acne and the application thereof has the following advantages:

(1) the acne-removing cream has the characteristics of high-efficiency acne-removing effect and the like, has no chemically synthesized acne-removing components, has no drug resistance and potential safety hazards, and has good market value and application prospect;

(2) in the plant compound for inhibiting the pathogenic bacteria related to the acne, the raw materials are easily available, in addition, the paris polyphylla has certain effects of clearing heat and removing toxicity, relieving swelling and pain, the magnolia officinalis has certain effects of promoting qi circulation and removing dampness, warming middle energizer and relieving pain, and the rheum officinale has certain effects of promoting diuresis and removing jaundice, detoxifying and eliminating carbuncle and has good potential application value.

Drawings

FIG. 1 is an HPLC chart showing the contents of rhizoma paridis saponin II and dioscin in the rhizoma paridis stem and leaf extract during calibration;

FIG. 2 is an HPLC chart showing the content calibration of honokiol and magnolol in Magnolia officinalis extract;

FIG. 3 is an HPLC chart showing the calibration of chrysophanol content in the Rheum officinale extract.

Detailed Description

In order that those skilled in the art will better understand the technical solution of the present invention, the following detailed description is given with reference to the accompanying drawings:

referring to fig. 1, the method for calibrating the contents of paris polyphylla saponin II and dioscin in the paris polyphylla stem and leaf extract comprises the following steps:

HPLC conditions, liquid phase column: agilent ZorbaxAq (4.6 × 250mm,5 μm), wavelength: 203nm, column temperature: 35 ℃, mobile phase: 0-50min, 70% pure water, 30% acetonitrile; 50-55min, 35% pure water and 65% acetonitrile; 55-60 min, 70% pure water and 30% acetonitrile.

According to the HPLC conditions, the concentration (C) of the paris saponin II is taken as the abscissa, and the peak area (S) is taken as the ordinate, so as to obtain the paris saponin II linear equation: 2703.4C +0.9794, R²The concentration range of the compound (0.0033-0.1050 mg/mL) is 0.9999^-1) The interior of the filter has good linear relation; taking the concentration (C) of the dioscin as a horizontal coordinate and the peak area (S) as a vertical coordinate to obtain a dioscin linear equation: 1227.4C +0.7129, R²The concentration range (0.0041-0.1300 mg/mL) is 0.9999^-1) The interior of the filter has good linear relation; repeated experiments prove that in the paris polyphylla stem and leaf extract, the mass percentage of the paris polyphylla saponin II is not less than 3 percent, and the mass percentage of the dioscin is not less than 3.5 percent.

Referring to fig. 2, the method for calibrating the content of honokiol and magnolol in magnolia bark extract is as follows:

HPLC conditions, liquid phase column: agilent Zorbax C18(4.6 x 250mm,5 μm), wavelength: 294nm, column temperature: 35 ℃, mobile phase: 0-25min, 30% methanol and 70% water.

According to the HPLC conditions, taking the magnolol concentration (C) as a horizontal coordinate and the peak area (S) as a vertical coordinate to obtain a magnolol linear equation: 14252C +34.956, R²0.9994, in the concentration range (0.01-1.43 mg. mL)^-1) The interior of the filter has good linear relation; taking the concentration (C) of honokiol as a horizontal coordinate and the peak area (S) as a vertical coordinate to obtain a honokiol linear equation: 14631C +10.872, R²0.999 at the concentration range (0.01-1.01 mg/mL)^-1) The interior of the filter has good linear relation; measuring magnolol and honokiol content in cortex Magnolia officinalis extract, and determining concentration in the above range by parallel measurement for three timesAnd carrying out a linear equation of the magnolol and the honokiol. Repeated experiments prove that in the magnolia officinalis extract, the weight percentage of honokiol is not less than 3.5%, and the weight percentage of magnolol is not less than 6.5%.

Referring to fig. 3, the method for calibrating the chrysophanol content in the rhubarb extract is as follows:

HPLC conditions, liquid phase column: agilent Zorbax C18(4.6 x 250mm,5 μm), wavelength: 254nm, column temperature: 35 ℃, mobile phase: 0-20min, 80% methanol, 20% 1% acetic acid water solution.

According to the HPLC conditions, the chrysophanol concentration (C) is taken as a horizontal coordinate, and the peak area (S) is taken as a vertical coordinate, so that a chrysophanol linear equation is obtained: 20517C-4.6506, R²The concentration range (0.0053-0.1680 mg/mL) was 0.9999^-1) The interior of the filter has good linear relation; repeating experiments to determine that the mass percentage content of chrysophanol in the rhubarb extract is not less than 1%.

Bacteriostatic MIC test

In order to reasonably compound the paris polyphylla stem and leaf extract, the magnolia officinalis extract and the rheum officinale extract in the subsequent process, the paris polyphylla stem and leaf extract, the magnolia officinalis extract, the rheum officinale extract and main functional monomers thereof are required to be prepared: the method for determining the antibacterial MIC of the paris polyphylla saponin II, the dioscin, the honokiol, the magnolol and the chrysophanol comprises the following specific experimental methods:

selecting resuscitation and acne related pathogenic bacteria: propionibacterium acnes (ATCC 11827), Staphylococcus aureus (ATCC 6538), and Staphylococcus epidermidis (ATCC 11228), and bacterial suspensions (OD 600: about 0.25) with a specific concentration were prepared by counting, diluting, and the prepared bacterial suspensions were stored at 4 ℃ for use.

And (3) determining the bacteriostatic MIC of the Propionibacterium acnes: under the anaerobic condition, the paris polyphylla stem and leaf extract is prepared into paris polyphylla stem and leaf extracting solution with specific concentration by a sesquidilution method, 3mL of paris polyphylla stem and leaf extracting solution and 3mL of brain heart infusion medium (BHI) are added into each test tube, and 0.3mL of bacterial suspension is added, so that the concentration of propionibacterium acnes in each tube is ensured to be 1-6 x 10⁸CFU/mL, setting positive and negative control groups, culturing at 37 deg.C for 96h, comparing by turbidity, addingThe minimum concentration of the paris polyphylla stem and leaf extract under the clear condition is the antibacterial MIC of the paris polyphylla stem and leaf extract. The stem and leaf extract of rhizoma paridis can be replaced by cortex Magnolia officinalis extract, radix et rhizoma Rhei extract, rhizoma paridis saponin II, dioscin, honokiol, magnolol, and chrysophanol, and the method is also suitable.

And (3) determining the bacteriostatic MIC of staphylococcus aureus and staphylococcus epidermidis: under the condition of normal temperature, the extract of the stem and leaf of the paris polyphylla is prepared into extract of the stem and leaf of the paris polyphylla with specific concentration by a sesquidilution method, 3mL of extract of the stem and leaf of the paris polyphylla and 3mL of Trypticase Soy Broth (TSB) are added into each test tube, and 0.3mL of bacterial suspension is added, so that the concentration of staphylococcus aureus and staphylococcus epidermidis in each tube is ensured to be 1-6 multiplied by 10⁸And (3) setting positive and negative control groups, culturing for 24h at the temperature of 30 ℃, and obtaining the antibacterial MIC of the paris polyphylla stem and leaf extract by comparing turbidity and taking the paris polyphylla stem and leaf extract as the minimum concentration of the paris polyphylla stem and leaf extract under the clear condition by adding the paris polyphylla stem and leaf extract. The stem and leaf extract of rhizoma paridis can be replaced by cortex Magnolia officinalis extract, radix et rhizoma Rhei extract, rhizoma paridis saponin II, dioscin, honokiol, magnolol, and chrysophanol, and the method is also suitable.

Antibacterial MIC determination of paris polyphylla stem and leaf extract, magnolia officinalis extract, rhubarb extract, paris polyphylla saponin II, dioscin, honokiol, magnolol and chrysophanol aiming at acne-related pathogenic bacteria is carried out, and specific experimental results are shown in Table 1:

TABLE 1

According to the antibacterial MIC data, the paris polyphylla stem and leaf extract and the monomer thereof, the magnolia officinalis extract and the monomer thereof, and the rheum officinale extract and the monomer thereof have relatively excellent antibacterial ability against acne-related pathogenic bacteria, and the antibacterial ability of the paris polyphylla stem and leaf extract, the magnolia officinalis extract and the monomer thereof can be improved after the paris polyphylla stem and leaf extract, the magnolia officinalis extract and the monomer thereof are compounded, so that the compounding result can be better described, and.

Example 1:

a plant compound for inhibiting acne related pathogenic bacteria comprises the following components in parts by weight: 20 parts of paris polyphylla stem and leaf extract; 40 parts of magnolia officinalis extract; 40 parts of rhubarb extract, and the sum of the parts by weight of the plant extracts is 100 parts.

The preparation process of the paris polyphylla stems and leaves comprises the following steps: weighing a proper amount of a paris polyphylla stem and leaf dry medicinal material, crushing the paris polyphylla stem and leaf dry medicinal material, adding the crushed paris polyphylla stem and leaf dry medicinal material into a methanol/water mixed solution with the volume fraction of 40%, carrying out reflux extraction for 2 times at the temperature of 75 ℃, combining the two extracting solutions, and sequentially carrying out reduced pressure concentration and water bath evaporation to dryness to obtain a paris polyphylla stem and leaf crude extract; separating and purifying the obtained crude extract of the stem and leaf of the paris polyphylla by HPD-100 macroporous resin to obtain the extract of the stem and leaf of the paris polyphylla.

The preparation process of the magnolia bark extract comprises the following steps: weighing a proper amount of dry magnolia officinalis medicinal materials, crushing, adding into an ethanol/water mixed solution with the volume fraction of 50%, wherein the material-liquid ratio of the dry magnolia officinalis medicinal materials to the ethanol/water mixed solution is 1:20kg/L, carrying out reflux extraction for 3 times at 75 ℃, combining obtained extracting solutions, and sequentially carrying out reduced pressure concentration and water bath evaporation to dryness to obtain the magnolia officinalis extract.

The preparation process of the rhubarb extract comprises the following steps: weighing a proper amount of dried rhubarb, crushing, adding into a pentanediol/water mixed solution with the volume fraction of 50%, wherein the material-liquid ratio of the dried rhubarb to the pentanediol/water mixed solution is 1:6kg/L, carrying out reflux extraction for 2 times at 75 ℃, combining the two extracting solutions, and sequentially carrying out reduced pressure concentration and water bath evaporation to dryness to obtain a rhubarb extract.

Example 2:

a plant compound for inhibiting acne related pathogenic bacteria comprises the following components in parts by weight: 30 parts of paris polyphylla stem and leaf extract; 30 parts of magnolia officinalis extract; 40 parts of rhubarb extract, and the sum of the parts by weight of the plant extracts is 100 parts.

The preparation process of the paris polyphylla stems and leaves comprises the following steps: weighing a proper amount of dry paris polyphylla stem and leaf medicinal materials, crushing, adding into a butanediol/water mixed solution with the volume fraction of 50%, wherein the material-liquid ratio of the dry paris polyphylla stem and leaf medicinal materials to the butanediol/water mixed solution is 1:10kg/L, carrying out reflux extraction for 3 times at the temperature of 75 ℃, combining obtained extracting solutions, and sequentially carrying out reduced pressure concentration and water bath evaporation to dryness to obtain a crude paris polyphylla stem and leaf extract; and separating and purifying the obtained crude extract of the stems and leaves of the paris polyphylla by using DM-301 macroporous resin to obtain the extract of the stems and leaves of the paris polyphylla.

The preparation process of the magnolia bark extract comprises the following steps: weighing a proper amount of dry magnolia officinalis medicinal materials, crushing, adding into a methanol/water mixed solution with the volume fraction of 60%, wherein the material-to-liquid ratio of the dry magnolia officinalis medicinal materials to the methanol/water mixed solution is 1:15kg/L, carrying out reflux extraction for 2 times at 75 ℃, combining obtained extracting solutions, and sequentially carrying out reduced pressure concentration and water bath evaporation to dryness to obtain the magnolia officinalis extract.

The preparation process of the rhubarb extract comprises the following steps: weighing a proper amount of dried rhubarb, crushing, adding into an ethanol/water mixed solution with the volume fraction of 40%, wherein the material-liquid ratio of the dried rhubarb to the ethanol/water mixed solution is 1:20kg/L, carrying out reflux extraction for 4 times at 75 ℃, combining the obtained extracting solutions, and sequentially carrying out reduced pressure concentration and water bath evaporation to dryness to obtain a rhubarb extract.

Example 3:

a plant compound capable of inhibiting acne related pathogenic bacteria comprises the following components in parts by mass: 40 parts of paris polyphylla stem and leaf extract; 40 parts of magnolia officinalis extract; 20 parts of rhubarb extract, and the sum of the parts by weight of the plant extracts is 100 parts.

The preparation process of the paris polyphylla stems and leaves comprises the following steps: weighing a proper amount of a paris polyphylla stem and leaf dry medicinal material, crushing, adding into a methanol/water mixed solution with the volume fraction of 95%, wherein the material-to-liquid ratio of the paris polyphylla stem and leaf dry medicinal material to the methanol/water mixed solution is 1:20kg/L, carrying out reflux extraction for 2 times at the temperature of 75 ℃, combining obtained extracting solutions, and sequentially carrying out reduced pressure concentration and water bath evaporation to dryness to obtain a paris polyphylla stem and leaf crude extract; and separating and purifying the obtained crude extract of the stems and leaves of the paris polyphylla by using D101 macroporous resin to obtain the extract of the stems and leaves of the paris polyphylla.

The preparation process of the magnolia bark extract comprises the following steps: weighing a proper amount of dry magnolia officinalis medicinal materials, crushing, adding into 95% by volume of butanediol/water mixed solution, wherein the material-to-liquid ratio of the dry magnolia officinalis medicinal materials to the butanediol/water mixed solution is 1:15kg/L, carrying out reflux extraction for 3 times at 75 ℃, combining obtained extracting solutions, and sequentially carrying out reduced pressure concentration and water bath evaporation to dryness to obtain the magnolia officinalis extract.

The preparation process of the rhubarb extract comprises the following steps: weighing a proper amount of dried rhubarb medicinal materials, crushing, adding into 60 volume percent of pentanediol/water mixed liquor, carrying out reflux extraction for 2 times at 75 ℃ with the material-liquid ratio of the dried rhubarb medicinal materials to the pentanediol/water mixed liquor being 1:10kg/L, combining the obtained extracting solutions, and sequentially carrying out reduced pressure concentration and water bath evaporation to dryness to obtain a rhubarb extract.

Examples the resulting plant complex bacteriostatic MIC tests:

in order to verify the bacteriostasis efficacy of the composite of the paris polyphylla stem and leaf extract, the magnolia officinalis extract and the rhubarb extract on the acne-related pathogenic bacteria, the plant compound obtained in the above examples 1-3 is subjected to a specific experiment for determining the bacteriostasis MIC of the acne-related pathogenic bacteria, and the results are shown in Table 2:

MIC(mg·mL^-1)	propionibacterium acnes	Staphylococcus aureus	Staphylococcus epidermidis
				Plant complexes of example 1	0.3	0.3	0.3
Plant complexes of example 2	0.15	0.15	0.3
				Plant complexes of example 3	0.3	0.3	0.3

TABLE 2

According to the test data in table 2, it can be known that the antibacterial efficacy against acne-related pathogenic bacteria is improved to different degrees by compounding the paris polyphylla stem and leaf extract, the magnolia officinalis extract and the rheum officinale extract.

Application example:

in order to better verify the bacteriostatic effect of the plant compound with the acne-related pathogenic bacteria inhibiting effect obtained in the examples 1 to 3, the plant compound is applied to actual moisturizing cream and moisturizing water, the mass of the plant compound is 0.3 to 0.5 percent of the total mass of the cosmetics, wherein all the raw materials are in parts by mass, the plant compound obtained in the examples 1 to 3 is applied to the moisturizing cream, and the formula of each component of the moisturizing cream is shown in table 3:

TABLE 3

The plant compound obtained in the example 1-3 is applied to the skin lotion, and the formula of each component of the skin lotion is shown in the table 4:

name of raw materials	Application example 4	Application example 5	Application example 6
				Glycerol	3.00	3.00	3.00
Glycerol polyether-26	2.00	2.00	2.00
				Hydroxyethyl cellulose	0.10	0.10	0.10
Hyaluronic acid sodium salt	0.10	0.10	0.10
				Beta-glucose	3.00	3.00	3.00
Purslane extract	0.10	0.10	0.10
				EXAMPLE 1 preparation of composites	0.30	-	-
EXAMPLE 2 preparation of composites	-	0.40	-
				EXAMPLE 3 preparation of composites	-	-	0.50
Water (W)	91.40	91.30	91.20

TABLE 4

Application examples 1-3 of the plant compound provided by the invention applied to moisturizing cream are prepared according to the formula in table 3.

Application examples 4-6 of the plant composite applied to skin moistening water are prepared according to the formula in the table 4.

The sources of the above raw materials are shown in table 5:

TABLE 5

Antibacterial testing experiment:

in order to verify the effect of the plant compound on inhibiting the pathogenic bacteria related to the acne, the antibacterial performance of the application examples 1-6 of the invention is determined by referring to GB15979-2002 'appendix C4 of hygienic Standard for Disposable sanitary articles' appendix C4 'test method for antibacterial performance of dissoluble antibacterial (inhibiting) products', and the specific experimental method is as follows:

preparing a bacterial suspension: and (3) eluting the 72h culture of the propionibacterium acnes by using 0.03mol/L phosphate buffer solution to prepare a bacterial suspension with OD600 equal to 0.25 (the bacterial suspension preparation method is still applicable after the propionibacterium acnes is replaced by staphylococcus epidermidis and staphylococcus aureus).

1g of the samples obtained in application examples 1-6 are respectively taken, 0.1mL of the bacterial suspension is added for uniform coating and mixing, 0.03mol/L of phosphate buffer solution is accurately added for uniform mixing after timing for 20min, 3 dilutions are taken, 1mL of the dilutions are respectively put into 2 parallel plates, and a corresponding culture medium is added for 24h under the anaerobic condition at 37 ℃ (in the method, the culture condition is changed into the aerobic culture condition at 25 ℃, namely, the method is suitable for staphylococcus epidermidis and staphylococcus aureus), and the bacterial colonies are counted. The above experiment was repeated 3 times, and the average value was taken to set a blank control group.

The method for calculating the bacteriostasis rate comprises the following steps: and X is (A-B)/A multiplied by 100 percent, wherein X is the bacteriostasis rate, A is the average recovered colony number of the control sample, and B is the average recovered colony number of the test sample.

Evaluation criteria for efficacy: (1) the bacteriostasis rate is more than or equal to 90 percent, and is obvious and effective; (2) the bacteriostasis rate is 50 to 90 percent effective; (3) the bacteriostasis rate is less than 50 percent, which is ineffective.

Through the above-mentioned experimental antibacterial test, test application example 1 ~ 6 gained the antibacterial effect of sample, and specific antibacterial test experimental result is shown in table 6:

test sample

Application example 1

Application example 2

Application example 3

Application example 4

Application example 5

Application example 6

Propionibacterium acnes inhibition rate (%)

91

95

90

98

93

95

Evaluation of efficacy

Is remarkably effective

Staphylococcus aureus inhibitory rate (%)

93

96

93

97

96

92

Evaluation of efficacy

Is remarkably effective

Staphylococcus epidermidis bacteriostasis rate (%)

94

97

94

92

94

97

Evaluation of efficacy

Is remarkably effective

TABLE 6

The antibacterial test results obtained in table 6 show that the cosmetics containing the phytocomplex obtained in application examples 1-6 all have significant and effective antibacterial ability, which shows that the phytocomplex of the present invention can significantly inhibit the proliferation of acne-related pathogenic bacteria, can effectively prevent or improve skin acne symptoms, and has good market value and application prospect.

In conclusion, the plant compound capable of inhibiting the pathogenic bacteria related to the acne is prepared by reasonably compounding the paris polyphylla stem and leaf extract, the magnolia officinalis extract and the rheum officinale extract, raw materials are easily obtained, the paris polyphylla has certain effects of clearing heat and removing toxicity, relieving swelling and pain, the magnolia officinalis has certain effects of promoting qi circulation and resolving dampness, warming the middle-jiao and relieving pain, and the rheum officinale has certain effects of promoting diuresis and removing jaundice, detoxifying and eliminating carbuncle; the plant compound has the excellent characteristics of high safety, obvious acne inhibition and the like, has no chemically synthesized acne removing components, has no drug resistance and potential safety hazards, and has good market value and application prospect.

It should be understood by those skilled in the art that the above embodiments are only for illustrating the present invention and are not to be used as a limitation of the present invention, and that changes and modifications to the above described embodiments are within the scope of the claims of the present invention as long as they are within the spirit and scope of the present invention.

Claims

1. The plant compound capable of inhibiting acne-related pathogenic bacteria is characterized by comprising the following components in parts by weight:

10-40 parts of paris polyphylla stem and leaf extract;

10-40 parts of magnolia officinalis extract;

10-40 parts of a rhubarb extract;

2. The plant compound for inhibiting the pathogenic bacteria related to the acne as claimed in claim 1, wherein the preparation process of the extract of the stem and leaf of the paris polyphylla is as follows: weighing a proper amount of dried paris polyphylla stem and leaf medicinal materials, crushing, adding the crushed medicinal materials into an alcohol/water mixed solution, performing reflux extraction for 1-4 times, mixing obtained extracting solutions, and sequentially performing reduced pressure concentration and water bath evaporation to dryness to obtain a crude extract of paris polyphylla stem and leaf; separating and purifying the crude extract of the stems and leaves of the paris polyphylla by macroporous resin to obtain the extract of the stems and leaves of the paris polyphylla;

3. A phytocomplex with acne related pathogen inhibition according to claim 1 or 2 wherein the paris polyphylla saponin II content is not less than 3% and the dioscin content is not less than 3.5% in the paris polyphylla stem and leaf extract.

4. The phytocomplex for inhibiting acne related pathogens according to claim 1 wherein Magnolia bark extract is prepared by the process of: weighing a proper amount of magnolia officinalis dry medicinal materials, crushing, adding the crushed magnolia officinalis dry medicinal materials into an alcohol/water mixed solution, performing reflux extraction for 1-4 times, mixing obtained extracting solutions, and performing reduced pressure concentration and water bath evaporation to dryness in sequence to obtain a magnolia officinalis extract;

5. The phytocomplex having an acne-related pathogen inhibition effect according to claim 1 or 4 wherein the magnolia bark extract has a honokiol content of not less than 3.5% by weight and a magnolol content of not less than 6.5% by weight.

6. The phytocomplex for inhibiting acne-related pathogens according to claim 1 wherein said rhubarb extract is prepared by the process comprising: weighing a proper amount of dried rhubarb, crushing, adding the crushed dried rhubarb into an alcohol/water mixed solution, performing reflux extraction for 1-4 times, mixing obtained extracting solutions, and performing reduced pressure concentration and water bath evaporation to dryness in sequence to obtain a rhubarb extract;

7. The phytocomplex having the effect of inhibiting acne-related pathogenic bacteria according to claim 1 or 6, wherein the rhein content in the rheum officinale extract is not less than 1% by mass.

8. The use of a phytocomplex for inhibiting acne-related pathogens according to claim 1, wherein the phytocomplex is added to a cosmetic, and the mass of the phytocomplex is 0.3 to 0.5% of the total mass of the cosmetic; the cosmetic is moisturizing cream or moisturizing lotion.

9. The use of a phytocomplex for inhibiting acne related pathogens according to claim 8 wherein said moisturizer comprises the following components in parts by weight: 0.01-0.05 part of acrylic acid (ester), 0.8-1.2 parts of polydimethylsiloxane, 0.01-0.03 part of xanthan gum, 0.01-0.03 part of sodium hyaluronate, 0.01-0.03 part of hyaluronic acid, 1-3 parts of tridecanol trimellitate, 1-3 parts of shea butter, 0.05-0.15 part of prinsepia utilis royle oil, 0.5-0.15 part of glycerol stearate, 1-5 parts of purslane extract, 0.05-0.15 part of aminomethyl propanol, 0.3-0.5 part of plant compound and the balance of water;

10. The use of a phytocomplex for inhibiting acne related pathogens according to claim 8 wherein said emollient water comprises the following components in parts by weight: 1-5 parts of glycerol, 261-5 parts of glycerol polyether, 0.03-0.08 part of hydroxyethyl cellulose, 0.01-0.05 part of sodium hyaluronate, 1-5 parts of beta-glucan, 1-5 parts of purslane extract, 0.3-0.5 part of the plant compound and the balance of water;